Announcement on the 2019 profit distribution plan.
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Pro 2020-005
Zhejiang Jianfeng Group Co., Ltd.
Announcement on 2019 Profit Distribution Plan
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Note:
- Distribution Ratio per Share: Cash Dividend 3.0 Yuan (Tax Included) for Every 10 Shares. No bonus shares will be distributed and no CPF capitalization will be made in 2019.
- This profit distribution is based on the total share capital registered on the equity registration date of the implementation of the equity distribution, and the specific date will be specified in the equity distribution implementation announcement.
- If the total share capital of the company changes before the equity registration date for the implementation of the equity distribution, it is proposed to maintain the distribution ratio per share unchanged and adjust the total distribution accordingly, and the specific adjustment will be announced separately.
- Brief description of this year's profit distribution plan: At present, the company is in the stage of accelerated development. In 2020, the company will accelerate the promotion of Guizhou peak daily production of 4500 tons of cement clinker new dry cement production line off-site technical transformation (with waste heat power generation) project, peak pharmaceutical Jinxi production base annual output of 2 billion pieces of solid preparation project, Anhui Zhongwang phase II technical transformation project, new Beika chemical technical transformation project and other projects under construction. In addition, Spike Pharmaceuticals has a number of new drugs in various stages of research and development, anti-tumor drug "DPT" has entered the clinical stage, the need to increase research and development investment. The development of the above-mentioned business requires large financial support. The content of
1. profit distribution plan
was audited by Tianjian Certified Public Accountants (Special General Partnership). The net profit attributable to the shareholders of the parent company in the consolidated statement of the company in 2019 was ,724,688,055.43 yuan. The net profit of the parent company's accounting statement ,267,306,832.98 yuan. According to the parent company's current net profit as the base, extract 10% statutory provident fund 26,730,683.30 yuan, plus undistributed profit 1,014,878,186.69 yuan at the beginning of the year, minus 2018 annual cash dividend 103,225,148.40 yuan, and the distributable profit for this year is 1,152,229,187.97 yuan.
Company plans to make cash distribution in 2019 , based on ,344,083, 828 shares at the end of 2019 , with cash dividends 3.0 yuan (tax included) for every 10 shares, and the total cash dividends to all shareholders registered on the date of record are 103,225,148.40 yuan (tax included).
No CPF conversion to share capital in 2019 .
If the total share capital of the Company changes due to the conversion of convertible bonds/ repurchase of shares / equity incentive grant of share repurchase and cancellation / major asset restructuring share repurchase and cancellation during the period from the date of disclosure of this announcement to the date of registration of equity distribution, the Company intends to maintain the distribution ratio per share and adjust the total distribution accordingly. If the subsequent total share capital changes, the specific adjustment will be announced separately.
This profit distribution plan still needs to be submitted to the general meeting of shareholders for consideration. During the reporting period of
, the net profit attributable to the shareholders of the listed company in the consolidated statement of the company was 724,688,055.43
yuan, the accumulated undistributed profit of the parent company was1,152,229,187.97 yuan, and the total cash dividend to be distributed by the listed company was 103,225,148.40 yuan (including tax), the proportion of net profit attributable to shareholders of listed companies this year is lower than 30% . The specific reasons are as follows: At present, the company is in the stage of accelerated development and has many construction projects. In 2020
, the company will continue to accelerate the construction of the project( estimated investment is 6.5 .2 billion ) of the new dry cement production line with a daily output of 4500 tons of cement clinker in Guizhou Huangping Jianfeng Cement Co., Ltd; the holding subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. Jinxi Production Base produces 20 .6 billion pieces of solid preparation project ( is expected to invest 50146 million yuan ) ; The holding subsidiary Anhui zhongwang pharmaceutical co., ltd. phase ii technological transformation project ( estimated total investment is 17500 .06 million yuan ) ; the construction and renovation of the technical renovation project ( is expected to invest 13274.25 .12 million yuan ) and other projects under construction by the end of 2019 , the above-mentioned projects have invested 4.91 .8 billion yuan. In addition, Jianfeng Pharmaceutical has a number of new drugs in various stages of research and development. The new anti-tumor drug "DPT " has entered the clinical stage. Jianfeng Pharmaceutical and its subsidiaries Zhejiang Erying Pharmaceutical Co., Ltd. and Zhejiang Jianfeng Yien Biotechnology Co., Ltd. will further increase product research and development and introduction, and need to increase research and development investment. The development of the above-mentioned business requires large financial support. 3. the decision-making procedure performed by the company
(I) the convening, deliberation and voting of the board meeting
2020
April# December August24 , the company held the 14th meeting of the 10th board of 131 by combining on-site and communication voting. the company currently has eight directors, all of whom attended the meeting in person, comply with the relevant provisions of the "Company Law" and the "Articles of Association", and the resolutions made are legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, the profit distribution plan of the company 2019 was deliberated and approved by 8 votes, 0 votes against, and 0 votes abstention. The board of directors of intends to submit the plan to the annual general meeting of shareholders of 2019 for deliberation. When the company holds the general meeting of shareholders, it will provide investors with convenient conditions for online voting.
(II) Independent Director's OpinionThe independent director of the company expressed the following opinions on the company's 2019
annual profit distribution plan:1
, agreeing that the company will pay a cash dividend of 3.0
yuan (including tax) for every10 shares based on 2019 year-end share capital ,344,083, 828 shares, the total amount of cash dividends distributed to all shareholders registered on the date of record is 103,225,148.40 yuan (including tax), 2019 year will not be converted into share capital. , the profit distribution plan is based on the actual operating results and financial situation of the Company
2019, combined with the actual needs of the Company's future business development. Retained undistributed profits are mainly used to meet the capital needs of the company's development, which is conducive to the sustainable and healthy development of the company, and there is no harm to the rights and interests of shareholders, especially small and medium shareholders. The independent directors are of the opinion that the profit distribution plan complies with the relevant provisions of the Articles of Association for profit distribution and the actual operating conditions of the Company. 3 , the company's board of directors considered and approved the above profit distribution plan. The Independent Directors are of the opinion that the convening, convening and deliberation and voting procedures of this meeting are in compliance with relevant laws, regulations and the Articles of Association of the Company, and are legal and effective; and agree to submit the proposal to the Company's
2019Annual General Meeting for consideration. (III) the opinions of the board of supervisors
2020, the company held the 184 meeting of the 9th 183 of the 9th board of supervisors. the company currently has five supervisors, all of whom attended the meeting in person, which conforms to the relevant provisions of the company law and the articles of association, and the resolution made is legal and effective. The meeting was presided over by Mr. Chen Tianci, Chairman of the Board of Supervisors. After deliberation and voting, the company's profit distribution plan for the year 2019 was deliberated and approved with 5 votes, 0 votes against, and 0 abstentions. Agree to submit to the general meeting of shareholders for consideration. The Board of Supervisors believes that: the company's 2019 profit distribution plan complies with the relevant provisions of the Articles of Association; the description of the profit distribution plan is objective and true, the decision-making procedures are in compliance, and meet the interests of all shareholders and the company's production and operation needs; No company profit distribution and cash dividend decisions were found to damage the legitimate rights and interests of shareholders.
4. Related Risk Reminder This profit distribution plan must be submitted to the company's 2019
annual general meeting for deliberation and approval before implementation. Investors are kindly requested to pay attention to investment risks.hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
April
28, 2002
More information
Teachers and Students of Zhejiang Gongshang University Visit Peak Health
News from our newspaper On the morning of June 9, a group of 18 teachers and students from Zhejiang Gongshang University came to Jianfeng Health for a visit and discussion, and conducted research on the establishment of Zhejiang Gongshang University Food Industrialization Research Institute in Jinhua. The leader of this visit is Professor Song Guanglei from the School of Food and Biological Engineering, Zhejiang Gongshang University. The teachers and students are mainly from the School of Food and Engineering, specializing in food science, food safety, biochemical and biotechnology, focusing on extraction and separation, functional activity and The research of functional food, in addition to the professor of the Department of E-commerce of the School of Management Engineering and E-commerce. Chen Daiyou, general manager of Jianfeng Health, Li Wende, deputy general manager, and relevant personnel from R & D, quality management, administrative personnel and other departments attended the forum. Li Wende introduced the basic situation, technical production level, scientific and technological research and development characteristics of Jianfeng Health Company in the form of PPT, as well as the relevant policies of Jinhua Municipal Government on talent introduction. Chen Daiyou focused on the development vision of Jianfeng Health Technology and the construction of scientific and technological talents, and welcomed graduate students from the Industrial and Commercial University to join the team of Jianfeng Health after graduation. Professor Song Guanglei fully affirmed the software and hardware facilities and humanistic management of Jianfeng Health Company. He said that most of the teachers and students who came to visit this time were professional in line with the industry of Jianfeng Health Company. The two sides could carry out in-depth cooperation in product development, technology upgrading and talent reserve. Fourteen graduate students also introduced their respective situations and study and research directions. After the symposium, the teachers and students visited the health company's testing center, R & D laboratory and plant extraction workshop with great interest.
2020
07-31
Trial operation of large pharmacy micro-mall
The construction of the micro-mall of Jianfeng Pharmacy is basically ready at present. On June 17, Shuangxi and Donglai chain stores took the lead in the trial operation of the micro-mall. At present, online consumption through computers and mobile phones has become a way of life in China. In particular, various software represented by WeChat covers more than 90% of smart phones, and has many functions such as information exchange and online payment. It is a new type of shopping system based on WeChat platform, using mobile Internet technology to realize the integration of online and offline marketing. At present, there are more than 1000 kinds of commodities on the shelves of the micro-mall of Jianfeng pharmacy, mainly OTC commodities of over-the-counter drugs, which are basically synchronized with pharmacies. Customers only need to pay attention to the public number of Jianfeng Pharmacy and enter the micro-mall to collect coupons through the "online drug purchase" on the public number page. They can find the required drugs on the mobile phone to purchase and pay for them. The delivery method can be delivered to the door or the store can pick them up by itself. The purchase of drugs through the micro-mall is not only convenient and fast, but also can reduce the phenomenon of queuing in the store. According to reports, the opening of the micro mall by the big pharmacy is to expand the new service model and provide more and better extended services to the masses. Prior to this, the WeChat public number of the large pharmacy has already made a useful attempt to push health information, and the operation of the micro-mall will further provide users with new channels for seeking medical advice. While further improving the micro-mall system, the large pharmacy will add "online pharmacists" and other service items to provide users with real-time consulting services such as medication guidance, drug purchase recommendation, health care knowledge and so on in the form of voice or text. (Tang Wenshu)
2020
07-31
Spike Health gets patent grants
Recently, Jianfeng Health Technology Company's invention patent "a low-temperature and low-pressure freeze-drying method for notoginseng chewable tablets" won a patent subsidy from Jinhua Science and Technology Bureau in 2017. In order to encourage invention and creation, promote independent innovation, promote the development of patented technology and products, and speed up the transformation of patent achievements, Jinhua Science and Technology Bureau gives invention patent subsidies to enterprises within its jurisdiction every year. Patent subsidies are declared once a year. After authorization, each domestic invention patent can receive a subsidy of 40000 yuan, including 20000 yuan in Jinhua City and 20000 yuan in the district. The invention patent of spike health "a low-temperature and low-pressure freeze-drying method of notoginseng chewable tablets" obtains notoginseng chewable tablets by washing, slicing and other pretreatment of fresh notoginseng main roots, then placing them in a vacuum dryer for vacuum freeze-drying. As the top high and new technology in the field of dehydration products, the whole freeze-drying process is carried out at low temperature, which avoids the quality deterioration reactions such as oxidation of active ingredients, destruction of volatile oil and other heat-sensitive substances in the traditional drying process. It can maximize the retention of various nutrients and active substances of medicinal materials and perfectly reproduce its initial type, color and taste, it has the characteristics of light weight, fast rehydration, convenient consumption and long storage period. The actual effect, appearance and color are basically the same as those of fresh Panax notoginseng. The effective ingredients are about 50% higher than those of products processed by traditional processes such as drying and drying. It is understood that the 2017 Jinhua patent subsidy of 20000 yuan obtained by Jianfeng Health is currently in place, and the application of patent subsidy in Wucheng District is in progress. (Xu Feng)
2020
07-31
Spike Health gets patent grants
Recently, Jianfeng Health Technology Company's invention patent "a low-temperature and low-pressure freeze-drying method for notoginseng chewable tablets" won a patent subsidy from Jinhua Science and Technology Bureau in 2017. In order to encourage invention and creation, promote independent innovation, promote the development of patented technology and products, and speed up the transformation of patent achievements, Jinhua Science and Technology Bureau gives invention patent subsidies to enterprises within its jurisdiction every year. Patent subsidies are declared once a year. After authorization, each domestic invention patent can receive a subsidy of 40000 yuan, including 20000 yuan in Jinhua City and 20000 yuan in the district. The invention patent of spike health "a low-temperature and low-pressure freeze-drying method of notoginseng chewable tablets" obtains notoginseng chewable tablets by washing, slicing and other pretreatment of fresh notoginseng main roots, then placing them in a vacuum dryer for vacuum freeze-drying. As the top high and new technology in the field of dehydration products, the whole freeze-drying process is carried out at low temperature, which avoids the quality deterioration reactions such as oxidation of active ingredients, destruction of volatile oil and other heat-sensitive substances in the traditional drying process. It can maximize the retention of various nutrients and active substances of medicinal materials and perfectly reproduce its initial type, color and taste, it has the characteristics of light weight, fast rehydration, convenient consumption and long storage period. The actual effect, appearance and color are basically the same as those of fresh Panax notoginseng. The effective ingredients are about 50% higher than those of products processed by traditional processes such as drying and drying. It is understood that the 2017 Jinhua patent subsidy of 20000 yuan obtained by Jianfeng Health is currently in place, and the application of patent subsidy in Wucheng District is in progress. (Xu Feng)
2020
07-30
Spike Health gets patent grants
Recently, Jianfeng Health Technology Company's invention patent "a low-temperature and low-pressure freeze-drying method for notoginseng chewable tablets" won a patent subsidy from Jinhua Science and Technology Bureau in 2017. In order to encourage invention and creation, promote independent innovation, promote the development of patented technology and products, and speed up the transformation of patent achievements, Jinhua Science and Technology Bureau gives invention patent subsidies to enterprises within its jurisdiction every year. Patent subsidies are declared once a year. After authorization, each domestic invention patent can receive a subsidy of 40000 yuan, including 20000 yuan in Jinhua City and 20000 yuan in the district. The invention patent of spike health "a low-temperature and low-pressure freeze-drying method of notoginseng chewable tablets" obtains notoginseng chewable tablets by washing, slicing and other pretreatment of fresh notoginseng main roots, then placing them in a vacuum dryer for vacuum freeze-drying. As the top high and new technology in the field of dehydration products, the whole freeze-drying process is carried out at low temperature, which avoids the quality deterioration reactions such as oxidation of active ingredients, destruction of volatile oil and other heat-sensitive substances in the traditional drying process. It can maximize the retention of various nutrients and active substances of medicinal materials and perfectly reproduce its initial type, color and taste, it has the characteristics of light weight, fast rehydration, convenient consumption and long storage period. The actual effect, appearance and color are basically the same as those of fresh Panax notoginseng. The effective ingredients are about 50% higher than those of products processed by traditional processes such as drying and drying. It is understood that the 2017 Jinhua patent subsidy of 20000 yuan obtained by Jianfeng Health is currently in place, and the application of patent subsidy in Wucheng District is in progress. (Xu Feng)
2020
07-31
On May 27, the Party Committee of the Group Company held a branch secretary meeting to comprehensively review and summarize the Party building work of the Company in 2016 and sign the responsibility book for the management of Party building work objectives in 2017. At the meeting, Qin xuping, member of the party Committee of the group company and director of the party-mass work department, made a comprehensive summary of the company's party building work in 2016, put forward the 2017 work plan, and conveyed the "key points of party building work in the city's two new organizations in 2017" issued by the two new working committees of Jinhua municipal party Committee, and the spirit of the speech made by the relevant leaders of the municipal party Committee at the recent meeting of the city's two new working committee, this paper explains the "ten questions" of the two new grass-roots party organizations, the "ten questions" of Party members and some problems that need attention in the process of Party member development. Members of the party committee of the group company, secretaries of grass-roots party committees and branch secretaries expressed their views and conducted extensive exchanges on such topics as how to deepen the "two learning and one doing", further play the role of party organizations in the process of enterprise operation and management, and how to do a good job in organizational construction in 2017. Jiang Xiaomeng, secretary of the party committee and chairman of the group company, on behalf of the party committee of the group, signed the 2017 party building work target management responsibility letter with the heads of the party organizations of various professional companies and directly affiliated enterprises. In his speech at the meeting, Jiang Xiaomeng said that the Politburo meeting of the CPC Central Committee held on the 26th reviewed and approved the "Decision on Amending the Regulations on the Inspection Work of the Communist Party of China" and other reports, which is a major measure to further implement the provisions of the party constitution and strengthen internal party supervision. Specific to the internal party building work of the enterprise, all cadres and party members should earnestly study relevant policies and documents, and earnestly understand the spirit of the central government
2020
07-31